News From Genomic Health

Positive Results of Largest Genomic Study in DCIS Reconfirm Oncotype DX is a Strong, Independent Predictor of Local Recurrence
Oral Presentation, Featured in the 2014 San Antonio Breast Cancer Symposium Press Program, to Occur on December 12 at 10:15 a.m. Central Time

SAN ANTONIO, Dec. 12, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive results from the second large clinical validation study of Oncotype DX® in patients with a pre-invasive form of breast cancer known as DCIS (ductal carcinoma in situ).  The study, conducted by the Ontario DCIS Study Group of Sunnybrook Health Sciences Centre in Canada, reconfirmed that the Oncotype DX DCIS Score is a strong predictor of local recurrence, which could be either invasive breast cancer or DCIS (p < 0.001). 

 

FDA Approves Liquid TREANDA®

The U.S. Food and Drug Administration (FDA) approved a liquid formulation of Teva Oncology’s TREANDA® (bendamustine HCI) Injection, for intravenous infusion. TREANDA is indicated for treatment of patients with: Chronic Lymphocytic Leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. Indolent B-cell non-Hodgkin Lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab containing regimen.

The LIQUID FORMULATION— TREANDA® (bendamustine HCl) Injection is available now. 

In addition to the Liquid formulation, TREANDA may still be available for a limited time as a single-use vial of lyophilized powder. 

Please click here for the Full TREANDA Liquid Formulation Prescribing Information.   

For more information about TREANDA, please visit: http://www.treanda.com.

 

Lilly's CYRAMZA Receives New FDA Indication

Eli Lilly and Company to announce that on November 5, 2014, the US Food and Drug Administration (FDA) approved a new indication for CYRAMZA® (ramucirumab). CYRAMZA as a single agent, or in combination with paclitaxel, is indicated for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. With this new indication, CYRAMZA can now be used for treatment as a single agent, or in combination with chemotherapy.

 

For more information, please visit www.CYRAMZAhcp.com.

 

Please click here for full Prescribing Information, including Boxed Warning for hemorrhage. 

 

Click here to read Lilly’s Press Release on CYRAMZA

 

Avastin Receives New FDA Indication

On November 14, 2014, Avastin® (bevacizumab) solution for intravenous infusion was approved by the FDA in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. 

Click Here to Access Practice Information from Genentech.

Click Here to read the entire prescribing information.

FDA Approves a New Indication for XTANDI® (enzalutamide) capsules

Astellas Pharma US, Inc. is pleased to announce that the US Food and Drug Administration (FDA) has approved a new indication for XTANDI, an androgen receptor inhibitor. XTANDI is now indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).

Please click here for Full Prescribing Information.

 

Velcade Receives New FDA Approval

Millennium: The Takeda Oncology Company is pleased to announce that VELCADE in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) is now approved for patients with previously untreated MCL. VR-CAP is the first and only FDA-approved regimen for the treatment of patients with previously untreated MCL. 

Click Here to read the announcement from Millennium. 

Click Here for full prescribing information.

 

FDA Approves a New Indication for XTANDI®

Astellas Pharma US, Inc. is pleased to announce that the US Food and Drug Administration (FDA) has approved a new indication for XTANDI, an androgen receptor inhibitor. XTANDI is now indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).1

For more information and to read the Safety Information go to www.xtandihcp.com   click here to view Full Prescribing Information.

MedImmune Metastatic Breast Cancer Campaign

More than 173,000 women in the United States are living with metastatic breast cancer (MBC), and each has a story to tell. Women with MBC encounter unique challenges, and it is often an important part of their journey to share their stories and connect with others who are living with the disease.

In support of women living with MBC, the MedImmune Specialty Care Division of AstraZeneca recently launched the #MBCStrength photo-sharing campaign. Women with MBC are encouraged to take photos of themselves that highlight their personal journeys and post them on Twitter with the hashtag #MBCStrength. Photos posted through October will be considered for a display in Times Square in New York City on October 13, 2014, Metastatic Breast Cancer Awareness Day.

For more information about the #MBCStrength photo-sharing campaign, visit www.MyMBCStory.com, a site that houses tools and information tailored for women living with MBC. New to the site are personal MBC accounts from Priscilla and Linda: two inspiring women who draw love and support from their family, friends and community.